# Biotech Daily Digest — 2026-02-12

**32 items from 5 sources**

## Summary by Source

- Endpoints News: 10 items
- Fierce Biotech: 7 items
- MHRA – News: 1 item
- Regeneron Press Releases: 1 item
- arXiv q-bio: 13 items


## Endpoints News

- **[Terray says its AI model beats Boltz-2 at binding affinity prediction](https://endpoints.news/terray-says-its-ai-model-beats-boltz-2-at-binding-affinity-prediction/)**  
  _Thu, 12 Feb 2026 13:00:16 +0000_  
  While most of AI drug discovery has followed AlphaFold with diffusion models, Terray Therapeutics says it has found success with a contrarian approach.

 In a recently posted preprint and blog post ...

- **[Lyell starts first head-to-head CAR-T therapy trial](https://endpoints.news/lyell-starts-first-head-to-head-car-t-therapy-trial/)**  
  _Thu, 12 Feb 2026 12:35:01 +0000_  
  Some cell therapy makers are employing an unprecedented but welcome strategy to forge the next wave of CAR-T treatments: making them beat the existing ones.
 Physicians have long preferred studies that pit one treatment directly ...

- **[BridgeBio's dwarfism drug succeeds in Phase 3, adding to recent late-stage wins](https://endpoints.news/bridgebios-dwarfism-drug-succeeds-in-phase-3-adding-to-recent-late-stage-wins/)**  
  _Thu, 12 Feb 2026 12:30:41 +0000_  
  BridgeBio said on Thursday that another of its Phase 3 rare disease studies succeeded, its third in the last few months, setting up a filing with the FDA.

 The latest win was in children with ...

- **[FDA may consider Moderna's flu vaccine in a narrower group](https://endpoints.news/fda-may-consider-modernas-flu-vaccine-in-a-narrower-group/)**  
  _Wed, 11 Feb 2026 21:06:04 +0000_  
  The FDA may be more willing to look at Moderna’s mRNA-based flu vaccine if the company re-filed it for a narrower group of older adults, a senior agency official told reporters in a call Wednesday ...

- **[Former AstraZeneca senior staff charged with illegal trade in China](https://endpoints.news/former-astrazeneca-senior-staff-charged-with-illegal-trade-in-china/)**  
  _Wed, 11 Feb 2026 20:24:40 +0000_  
  Chinese prosecutors have charged two of AstraZeneca’s former senior employees with illegal trade, unlawful collection of personal information, and medical insurance fraud, the company said this week.

 AstraZeneca disclosed the charges in its fourth-quarter earnings ...

- **[Prasad overruled vaccine review team, office director on Moderna flu shot](https://endpoints.news/prasad-overruled-vaccine-review-team-office-director-on-moderna-flu-shot/)**  
  _Wed, 11 Feb 2026 16:21:58 +0000_  
  Vinay Prasad, director of the FDA's office of biologics and vaccines, overruled both the vaccine review team and the head of the FDA's vaccine team as part of the ...

- **[After CEO departs, CSL details profit crash, $1.1B impairment costs](https://endpoints.news/after-ceo-departs-csl-details-profit-crash-1-1b-impairment-costs/)**  
  _Wed, 11 Feb 2026 16:18:10 +0000_  
  One day after bumping out CEO Paul McKenzie, Australia’s CSL revealed what he left behind: declining profit and a $1.1 billion hole due to lower US vaccine demand and increased generic competition.

 CSL

- **[Madrigal pads MASH pipeline with six siRNAs from China's Ribo](https://endpoints.news/madrigal-pads-mash-pipeline-with-six-sirnas-from-chinas-ribo/)**  
  _Wed, 11 Feb 2026 15:49:41 +0000_  
  Madrigal Pharmaceuticals is on a mission to become a generational, independent player in the MASH field with its third deal in eight months.

 The first FDA-approved medicine for the fatty liver disease, Rezdiffra, has now ...

- **[How a closet full of EKG machines illustrates pharma’s clinical trial cost problem](https://endpoints.news/how-a-closet-full-of-ekg-machines-illustrates-pharmas-clinical-trial-cost-problem/)**  
  _Wed, 11 Feb 2026 15:00:30 +0000_  
  When Jake Van Naarden visits a hospital running clinical trials, he runs into an odd sight.

 Van Naarden, the head of Eli Lilly's oncology unit, opens a supply closet and sees more than a dozen ...

- **[Upstream Bio's stock slides on Phase 2 severe asthma data for verekitug](https://endpoints.news/upstream-bio-says-verekitug-delivered-positive-data-in-phase-2-severe-asthma-trial/)**  
  _Wed, 11 Feb 2026 11:57:14 +0000_  
  Upstream Bio on Wednesday said its TSLP-targeting drug met its goal in a mid-stage trial in severe asthma, which is a step forward in its bid to challenge Dupixent and Tezspire down the line.  ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/medtech/agilent-lands-fda-nod-companion-diagnostic-keytrudas-latest-cancer-approval" hreflang="en">Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval</a>](https://www.fiercebiotech.com/medtech/agilent-lands-fda-nod-companion-diagnostic-keytrudas-latest-cancer-approval)**  
  _Feb 12, 2026 3:36am_  
  As Merck received its latest FDA nod for Keytruda in ovarian cancer, Agilent gained the green light for its accompanying test to identify patients who can best benefit from the drug.

- **[<a href="https://www.fiercebiotech.com/biotech/bridgebio-preps-approval-push-after-dwarfism-drug-increases-height-children-phase-3" hreflang="en">BridgeBio preps approval push after dwarfism drug increases children's height in phase 3</a>](https://www.fiercebiotech.com/biotech/bridgebio-preps-approval-push-after-dwarfism-drug-increases-height-children-phase-3)**  
  _Feb 12, 2026 6:04am_  
  BridgeBio is hoping that infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in a form of dwarfism in children.

- **[<a href="https://www.fiercebiotech.com/medtech/labcorp-launches-roches-fda-cleared-alzheimers-blood-test" hreflang="en">Labcorp launches Roche's FDA-cleared Alzheimer's blood test </a>](https://www.fiercebiotech.com/medtech/labcorp-launches-roches-fda-cleared-alzheimers-blood-test)**  
  _Feb 12, 2026 3:46am_  
  Labcorp is now offering Roche Diagnostics' recently FDA-cleared Alzheimer’s disease blood test to help primary care doctors rule out the disease in people 55 and older with symptoms of cognitive decline, the company announced Feb. 11.

- **[<a href="https://www.fiercebiotech.com/pharma/sanofi-ousts-paul-hudson-after-bumpy-ride-poaches-merck-kgaa-ceo-lead-company" hreflang="en">Sanofi ousts Paul Hudson after 'bumpy ride,' enlists Merck KGaA CEO to lead the French pharma</a>](https://www.fiercebiotech.com/pharma/sanofi-ousts-paul-hudson-after-bumpy-ride-poaches-merck-kgaa-ceo-lead-company)**  
  _Feb 12, 2026 4:27am_  
  Belén Garijo’s appointment restores a woman CEO to the ranks of the top 10 Big Pharma companies.

- **[<a href="https://www.fiercebiotech.com/biotech/takeda-consolidates-boston-footprint-630000-sf-offload" hreflang="en">Takeda downsizes Boston footprint amid consolidation effort</a>](https://www.fiercebiotech.com/biotech/takeda-consolidates-boston-footprint-630000-sf-offload)**  
  _Feb 11, 2026 3:03pm_  
  Massachusetts’ largest life science employer has put more than 630,000 square feet of office space on the sublease market as part of efforts to consolidate the Japanese company’s U.S. corporate hub at a new Cambridge development scheduled to open later this year.

- **[<a href="https://www.fiercebiotech.com/biotech/after-facing-modernas-ire-fda-stands-behind-decision-spurn-mrna-flu-filing" hreflang="en">UPDATE: After Moderna's rebuke, HHS stands behind FDA decision to spurn mRNA flu filing</a>](https://www.fiercebiotech.com/biotech/after-facing-modernas-ire-fda-stands-behind-decision-spurn-mrna-flu-filing)**  
  _Feb 11, 2026 2:09pm_  
  After the FDA's surprise refusal to take up a review of Moderna's next-gen flu vaccine, the public disagreement between U.S. regulators and the mRNA specialist took another turn Wednesday.

- **[<a href="https://www.fiercebiotech.com/biotech/only-thing-saves-us-data-allogeneic-car-t-biotechs-fight-relevance-industry-moves" hreflang="en">‘The only thing that saves us is data’: Allogeneic CAR-T biotechs fight for relevance as industry moves on</a>](https://www.fiercebiotech.com/biotech/only-thing-saves-us-data-allogeneic-car-t-biotechs-fight-relevance-industry-moves)**  
  _Feb 6, 2026 5:45pm_  
  Ever since 6-year-old Emily Whitehead became the first patient to receive CAR-T cell therapy in 2012, where T cells were removed from her body and reprogrammed to attack her leukemia before being reinfused, drug developers have tried to make the procedure more accessible to a broader range of patients.


## MHRA – News

- **[MHRA introduces additional restrictions for use of the Chikungunya vaccine (IXCHIQ)](https://www.gov.uk/government/news/mhra-introduces-additional-restrictions-for-use-of-the-chikungunya-vaccine-ixchiq)**  
  _2026-02-11T14:58:11Z_  
  The vaccine should not be used in people aged 60 or over, and in individuals of any age who have high blood pressure, heart disease, diabetes, or chronic kidney disease.


## Regeneron Press Releases

- **[Regeneron Announces Investor Conference Presentations](https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-presentations-23)**  
  _Wed, 11 Feb 2026 16:05:00 -0500_  
  TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:  REGN) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference at 9:10 a.m. ET on Wednesday,  March 4, 2026 Leerink Partners 2026 Global Healthcare Conference at 10:40


## arXiv q-bio

- **[Validating Interpretability in siRNA Efficacy Prediction: A Perturbation-Based, Dataset-Aware Protocol](https://arxiv.org/abs/2602.10152)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2602.10152v1 Announce Type: new 
Abstract: Saliency maps are increasingly used as \emph{design guidance} in siRNA efficacy prediction, yet attribution methods are rarely validated before motivating sequence edits. We introduce a \textbf{pre-synthesis gate}: a protocol for \emph{counterfactual sensitivity faithfu…

- **[STRAND: Sequence-Conditioned Transport for Single-Cell Perturbations](https://arxiv.org/abs/2602.10156)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2602.10156v1 Announce Type: new 
Abstract: Predicting how genetic perturbations change cellular state is a core problem for building controllable models of gene regulation. Perturbations targeting the same gene can produce different transcriptional responses depending on their genomic locus, including different…

- **[Beyond SMILES: Evaluating Agentic Systems for Drug Discovery](https://arxiv.org/abs/2602.10163)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2602.10163v1 Announce Type: new 
Abstract: Agentic systems for drug discovery have demonstrated autonomous synthesis planning, literature mining, and molecular design. We ask how well they generalize. Evaluating six frameworks against 15 task classes drawn from peptide therapeutics, in vivo pharmacology, and res…

- **[EVA: Towards a universal model of the immune system](https://arxiv.org/abs/2602.10168)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2602.10168v1 Announce Type: new 
Abstract: The effective application of foundation models to translational research in immune-mediated diseases requires multimodal patient-level representations that can capture complex phenotypes emerging from multicellular interactions. Yet most current biological foundation mo…

- **[ENIGMA: EEG-to-Image in 15 Minutes Using Less Than 1% of the Parameters](https://arxiv.org/abs/2602.10361)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2602.10361v1 Announce Type: new 
Abstract: To be practical for real-life applications, models for brain-computer interfaces must be easily and quickly deployable on new subjects, effective on affordable scanning hardware, and small enough to run locally on accessible computing resources. To directly address thes…

- **[Towards Universal Spatial Transcriptomics Super-Resolution: A Generalist Physically Consistent Flow Matching Framework](https://arxiv.org/abs/2602.10644)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2602.10644v1 Announce Type: new 
Abstract: Spatial transcriptomics provides an unprecedented perspective for deciphering tissue spatial heterogeneity. However, high-resolution spatial transcriptomic technology remains constrained by limited gene coverage, technical complexity, and high cost. Existing spatial tra…

- **[A Dynamical Microscope for Multivariate Oscillatory Signals: Validating Regime Recovery on Shared Manifolds](https://arxiv.org/abs/2602.11054)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2602.11054v1 Announce Type: new 
Abstract: Multivariate oscillatory signals from complex systems often exhibit non-stationary dynamics and metastable regime structure, making dynamical interpretation challenging. We introduce a ``dynamical microscope'' framework that converts multichannel signals into circular p…

- **[Whodunnit? The case of midge swarms](https://arxiv.org/abs/2602.10242)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2602.10242v1 Announce Type: cross 
Abstract: As collective states of animal groups go, swarms of midge insects pose a number of puzzling questions. Their ordering polarization parameter is quite small and the insects are weakly coupled among themselves but strongly coupled to the swarm. In laboratory studies (fr…

- **[Fragile $\mathit{vs}$ robust Multiple Equilibria phases in generalized Lotka-Volterra model with non-reciprocal interactions](https://arxiv.org/abs/2602.10856)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2602.10856v1 Announce Type: cross 
Abstract: We investigate the Multiple Equilibria phase of generalized Lotka-Volterra dynamics with random, non-reciprocal interactions. We compute the topological complexity of equilibria, which quantifies how rapidly the number of equilibria of the dynamical equations grows wi…

- **[Omnibenchmark: transparent, reproducible, extensible and standardized orchestration of solo and collaborative benchmarks](https://arxiv.org/abs/2409.17038)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2409.17038v2 Announce Type: replace 
Abstract: Benchmarking involves designing, running and disseminating rigorous performance assessments of methods, most often for data analysis and software tools, but the process can also be applied to experimental systems. Ideally, a benchmarking system is used to facilitate…

- **[Multi-modal Gaussian Process Variational Autoencoders for Neural and Behavioral Data](https://arxiv.org/abs/2310.03111)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2310.03111v2 Announce Type: replace-cross 
Abstract: Characterizing the relationship between neural population activity and behavioral data is a central goal of neuroscience. While latent variable models (LVMs) are successful in describing high-dimensional time-series data, they are typically only designed for a…

- **[Metareasoning in uncertain environments: a meta-BAMDP framework](https://arxiv.org/abs/2408.01253)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2408.01253v3 Announce Type: replace-cross 
Abstract: \textit{Reasoning} may be viewed as an algorithm $P$ that makes a choice of an action $a^* \in \mathcal{A}$, aiming to optimize some outcome. However, executing $P$ itself bears costs (time, energy, limited capacity, etc.) and needs to be considered alongside…

- **[MOTGNN: Interpretable Graph Neural Networks for Multi-Omics Disease Classification](https://arxiv.org/abs/2508.07465)**  
  _Thu, 12 Feb 2026 00:00:00 -0500_  
  arXiv:2508.07465v2 Announce Type: replace-cross 
Abstract: Integrating multi-omics data, such as DNA methylation, mRNA expression, and microRNA (miRNA) expression, offers a comprehensive view of the biological mechanisms underlying disease. However, the high dimensionality of multi-omics data, the heterogeneity across…
